Skip to content
MARKETS / NASDAQ / COCH
NASDAQ · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES

Envoy Medical, Inc. COCH

5 fiscal years on record · USD · FY2025 reported · SEC filings only
$241,000
▲ 7.1% YoY
$-23.8M
$-18.4M
In brief

What this company does

We are a hearing health company focused on providing innovative medical technologies across the hearing loss spectrum. Our first product, the Esteem FI-AMEI, received FDA approval in 2010. The Esteem FI-AMEI remains the only FDA approved fully implanted active hearing implant on the market. In late 2015, we made the decision to shift our focus from the Esteem FI-AMEI to a new product that would leverage our sensor technology and incorporate it into a cochlear implant. The Acclaim CI is fully implanted and does not have the need for any external component to be worn on the ear. The Acclaim CI received the Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2019.

Written from the business description in Envoy Medical, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 23 March 2026. Every sentence was checked against that document before publication.

Growth
USD 241,000.00
Revenue, FY2025 · full 5-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.2 · Net income -23.8
-10M-20M20212022202320242025
Compound annual growth
+0.6%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−9857 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -9240.7% · Net -9857.3%
5000%-5000%20212022202320242025
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Gross margin-262.7%
Operating margin-9240.7%
Net margin-9857.3%
Return on assets-236.4%
EBITDAUSD -22.0M

Cash & shareholders
USD 1.8M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -18.4
-8M-16M20212022202320242025
Net buybacks $M Dividends $M
FY2025 · Dividends 1.8 · Net buybacks —
1M2M20242025

USD 1.8M in dividends went back to shareholders in a year without profit.

Total assetsUSD 8.6M
EquityUSD -12.2M
CashUSD 3.7M
Current ratio0.54×

Equity funds -142% of total assets.

The 5-year record
5 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021
Revenue $B0.00.00.00.0·
Operating income $B−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0·
Income tax $B···0.0·
Net income $B−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0·
EPS, diluted $−1.23−1.49−2.54−1.57·
Dividend / sh $·····
Payout %−8−12···
ROE %·····
Shares out B··0.02··

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 19 reconciliationsAUDITED

Reconciled in 5 of 19 fiscal years. 72 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityOrthopedic, Prosthetic & Surgical Appliances & Supplies
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2021

Share this section

Download image